Cita APA

Ostorhazi, E., Hoffmann, R., Herth, N., Wade, J. D., Kraus, C. N., & Otvos Jr., L. (2018). Advantage of a Narrow Spectrum Host Defense (Antimicrobial) Peptide Over a Broad Spectrum Analog in Preclinical Drug Development. Front Chem.

Citación estilo Chicago

Ostorhazi, Eszter, Ralf Hoffmann, Nicole Herth, John D. Wade, Carl N. Kraus, y Laszlo Otvos Jr. "Advantage of a Narrow Spectrum Host Defense (Antimicrobial) Peptide Over a Broad Spectrum Analog in Preclinical Drug Development." Front Chem 2018.

Cita MLA

Ostorhazi, Eszter, et al. "Advantage of a Narrow Spectrum Host Defense (Antimicrobial) Peptide Over a Broad Spectrum Analog in Preclinical Drug Development." Front Chem 2018.